CD2019

Overview

CD2019 is a selective retinoic acid receptor β ( RARβ ) agonist, with a K d value of 26 nM for RARβ and an AC 50 value of 3.8 nM for human RARβ . CD2019 regulates downstream biological effects via the PI3K signaling pathway. CD2019 suppresses squamous metaplasia, inhibits squamous differentiation markers, maintains pseudostratified epithelial structure, induces neurite and axon growth, and promotes functional recovery; it exhibits cytotoxicity at higher concentrations and reduces endogenous retinol levels. CD2019 can be used in studies related to squamous metaplasia, spinal cord injury and embryonic malformations.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Nervous System Injury | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > RAR/RXR

Product Information

• Catalog No.: HY-183405
• CAS No.: 143984-56-9
• Molecular Formula: C25H26O3
• Molecular Weight: 374.47
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source